Praxis Precision Medicines I (PRAX)
$54.02
Performance
- $53.89$58.97$54.02
0.24%
Downside
Day's Volatility :8.61%
Upside
8.39%
- $1.11$67.21$54.02
97.95%
Downside
52 Weeks Volatility :98.35%
Upside
19.63%
Returns
| Period | Praxis Precision Medicines I | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 33.25% | 5.1% | 0.0% |
6 Months | -4.22% | 4.9% | 0.0% |
1 Year | 150.09% | 16.6% | 0.0% |
3 Years | -84.04% | 13.2% | -22.3% |
Highlights
Market Capitalization | 959.2M |
Book Value | $23.6 |
Earnings Per Share (EPS) | -5.59 |
Wall Street Target Price | 146.44 |
Profit Margin | 0.0% |
Operating Margin TTM | -10500.84% |
Return On Assets TTM | -28.87% |
Return On Equity TTM | -47.16% |
Revenue TTM | 1.8M |
Revenue Per Share TTM | 0.14 |
Quarterly Revenue Growth YOY | -54.300000000000004% |
Gross Profit TTM | 0.0 |
EBITDA | -132.3M |
Diluted Eps TTM | -5.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -8.49 |
EPS Estimate Next Year | -8.39 |
EPS Estimate Current Quarter | -2.31 |
EPS Estimate Next Quarter | -2.36 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 171.08%
Technicals Summary
Sell
Neutral
Buy
Praxis Precision Medicines I is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Praxis Precision Medicines I | 3.82% | -4.22% | 150.09% | -84.04% | -87.05% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Praxis Precision Medicines I | NA | NA | NA | -8.49 | -0.47 | -0.29 | NA | 23.6 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Praxis Precision Medicines I | Buy | $959.2M | -87.05% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Praxis Precision Medicines I
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 153.2%
Institutional Holdings
Cormorant Asset Management, LLC
7.38%BlackRock Inc
7.29%RA Capital Management, LLC
6.96%Adage Capital Partners Gp LLC
6.39%Point72 Asset Management, L.P.
5.92%Vanguard Group Inc
5.50%
Company Information
praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res
Organization | Praxis Precision Medicines I |
Employees | 82 |
CEO | Mr. Marcio Silva De'Souza M.B.A. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$54.02
-8.5%
Keyarch Acquisition Corp
$54.02
-8.5%
Connexa Sports Technologies Inc
$54.02
-8.5%
Us Value Etf
$54.02
-8.5%
First Wave Biopharma Inc
$54.02
-8.5%
Global X Msci Next Emerging
$54.02
-8.5%
Fat Projects Acquisition Corp
$54.02
-8.5%
Capital Link Global Fintech
$54.02
-8.5%
Applied Uv Inc
$54.02
-8.5%